Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
Identifieur interne : 001583 ( Main/Exploration ); précédent : 001582; suivant : 001584Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
Auteurs : Iracema Leroi [Royaume-Uni, États-Unis] ; Jason Brandt [États-Unis] ; Stephen G. Reich [États-Unis] ; Constantine G. Lyketsos [États-Unis] ; Stephen Grill [États-Unis] ; Richard Thompson [États-Unis] ; Laura Marsh [États-Unis]Source :
- International Journal of Geriatric Psychiatry [ 0885-6230 ] ; 2004-01.
English descriptors
- KwdEn :
Abstract
Objective: To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). Methods: Using a randomized, double‐blind, placebo‐controlled design, nine patients received placebo and seven patients received donepezil (2.5–10 mg/day) for a mean (SD) duration of 15.2 (3.4) weeks. The primary efficacy outcomes were derived from a neuropsychological battery that assessed global cognitive status as well as memory, attention, psychomotor speed, and visuospatial and executive functions. Secondary efficacy outcomes were psychiatric symptom and activities of daily living ratings. Primary safety measures were motor signs and assessments of adverse effects. Results: Patients on donepezil showed selective and significant (p<0.05) improvement on the memory subscale of the Dementia Rating Scale. There was also a trend toward improvement on a measure of psychomotor speed and attention. There were no group differences in psychiatric status, motor function, or activities of daily living as measured at baseline or end‐point. Adverse effects resulted in premature withdrawal of four patients on donepezil, two for peripheral cholinergic effects and one for increased parkinsonism. Side effects were associated with dosage increases. Conclusion: Donepezil has a beneficial effect on memory and may improve other cognitive deficits in patients with PD and cognitive impairment. However, variable tolerability in our sample underscores the need for careful monitoring when prescribing donepezil to patients with PD, especially with dosage increases. Copyright © 2004 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/gps.993
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease</title><author><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name></author><author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name></author><author><name sortKey="Reich, Stephen G" sort="Reich, Stephen G" uniqKey="Reich S" first="Stephen G." last="Reich">Stephen G. Reich</name></author><author><name sortKey="Lyketsos, Constantine G" sort="Lyketsos, Constantine G" uniqKey="Lyketsos C" first="Constantine G." last="Lyketsos">Constantine G. Lyketsos</name></author><author><name sortKey="Grill, Stephen" sort="Grill, Stephen" uniqKey="Grill S" first="Stephen" last="Grill">Stephen Grill</name></author><author><name sortKey="Thompson, Richard" sort="Thompson, Richard" uniqKey="Thompson R" first="Richard" last="Thompson">Richard Thompson</name></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8265EDC38D76DB29AD57ED76460E16871CB55CD3</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/gps.993</idno><idno type="url">https://api.istex.fr/document/8265EDC38D76DB29AD57ED76460E16871CB55CD3/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000E21</idno><idno type="wicri:Area/Main/Curation">000C54</idno><idno type="wicri:Area/Main/Exploration">001583</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease</title><author><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Department of Psychiatry, North Manchester General Hospital, Manchester</wicri:regionArea><placeName><settlement type="city">Manchester</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Manchester</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Reich, Stephen G" sort="Reich, Stephen G" uniqKey="Reich S" first="Stephen G." last="Reich">Stephen G. Reich</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Lyketsos, Constantine G" sort="Lyketsos, Constantine G" uniqKey="Lyketsos C" first="Constantine G." last="Lyketsos">Constantine G. Lyketsos</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Grill, Stephen" sort="Grill, Stephen" uniqKey="Grill S" first="Stephen" last="Grill">Stephen Grill</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Thompson, Richard" sort="Thompson, Richard" uniqKey="Thompson R" first="Richard" last="Thompson">Richard Thompson</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Biostatistics, Bloomberg School of Public Health and Hygiene, Johns Hopkins University, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">International Journal of Geriatric Psychiatry</title><title level="j" type="abbrev">Int. J. Geriat. Psychiatry</title><idno type="ISSN">0885-6230</idno><idno type="eISSN">1099-1166</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2004-01">2004-01</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="8">8</biblScope></imprint><idno type="ISSN">0885-6230</idno></series><idno type="istex">8265EDC38D76DB29AD57ED76460E16871CB55CD3</idno><idno type="DOI">10.1002/gps.993</idno><idno type="ArticleID">GPS993</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-6230</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson' s disease</term><term>cholinesterase inhibitors</term><term>cognitive impairment</term><term>dementia</term><term>donepezil</term><term>neuropsychiatry</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD). Methods: Using a randomized, double‐blind, placebo‐controlled design, nine patients received placebo and seven patients received donepezil (2.5–10 mg/day) for a mean (SD) duration of 15.2 (3.4) weeks. The primary efficacy outcomes were derived from a neuropsychological battery that assessed global cognitive status as well as memory, attention, psychomotor speed, and visuospatial and executive functions. Secondary efficacy outcomes were psychiatric symptom and activities of daily living ratings. Primary safety measures were motor signs and assessments of adverse effects. Results: Patients on donepezil showed selective and significant (p<0.05) improvement on the memory subscale of the Dementia Rating Scale. There was also a trend toward improvement on a measure of psychomotor speed and attention. There were no group differences in psychiatric status, motor function, or activities of daily living as measured at baseline or end‐point. Adverse effects resulted in premature withdrawal of four patients on donepezil, two for peripheral cholinergic effects and one for increased parkinsonism. Side effects were associated with dosage increases. Conclusion: Donepezil has a beneficial effect on memory and may improve other cognitive deficits in patients with PD and cognitive impairment. However, variable tolerability in our sample underscores the need for careful monitoring when prescribing donepezil to patients with PD, especially with dosage increases. Copyright © 2004 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Manchester</li><li>Maryland</li></region><settlement><li>Manchester</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name></region></country><country name="États-Unis"><region name="Maryland"><name sortKey="Leroi, Iracema" sort="Leroi, Iracema" uniqKey="Leroi I" first="Iracema" last="Leroi">Iracema Leroi</name></region><name sortKey="Brandt, Jason" sort="Brandt, Jason" uniqKey="Brandt J" first="Jason" last="Brandt">Jason Brandt</name><name sortKey="Grill, Stephen" sort="Grill, Stephen" uniqKey="Grill S" first="Stephen" last="Grill">Stephen Grill</name><name sortKey="Lyketsos, Constantine G" sort="Lyketsos, Constantine G" uniqKey="Lyketsos C" first="Constantine G." last="Lyketsos">Constantine G. Lyketsos</name><name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name><name sortKey="Reich, Stephen G" sort="Reich, Stephen G" uniqKey="Reich S" first="Stephen G." last="Reich">Stephen G. Reich</name><name sortKey="Thompson, Richard" sort="Thompson, Richard" uniqKey="Thompson R" first="Richard" last="Thompson">Richard Thompson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001583 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001583 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8265EDC38D76DB29AD57ED76460E16871CB55CD3
|texte= Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |